Clinical Trial

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Study acronym: TRILOGY
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
Protocol Amendment History 4 changes
notable Trial sites expanded: 42 -> 47 locations 2026-06-12
minor Completion pushed: 2031-12-12 -> 2032-02-25 2026-06-12
notable Trial sites expanded: 38 -> 42 locations 2026-05-09
notable Trial sites expanded: 30 -> 38 locations 2026-04-14
Trial Details
NCT Number NCT06663332
Lead Sponsor Janssen Research & Development, LLC
Conditions Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Enrollment 196 participants
Start Date 2024-10-29
Primary Completion 2031-12-12 (estimated)
Study Completion 2032-02-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-06